Double maintains 1 strategies that include ALXO - ALX Oncology Holdings, Inc.
Current Value
$0.581 Year Return
Current Value
$0.581 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CHRW | -20.87% | $12.16B | +43.26% | 2.56% |
TMUS | -17.41% | $302.06B | +62.05% | 1.14% |
WEC | -16.52% | $34.37B | +34.01% | 3.09% |
CWAN | -16.05% | $6.38B | +55.77% | 0.00% |
CNP | -15.41% | $24.07B | +31.19% | 2.21% |
APD | -14.99% | $65.62B | +23.11% | 2.49% |
SO | -14.66% | $100.14B | +28.63% | 3.09% |
VSTA | -14.31% | $366.38M | +18.55% | 0.00% |
AEE | -14.29% | $27.24B | +37.85% | 2.66% |
OMCL | -14.12% | $1.66B | +28.62% | 0.00% |
EXAS | -13.71% | $8.28B | -38.81% | 0.00% |
DOGZ | -13.61% | $372.37M | +260.22% | 0.00% |
PPC | -13.58% | $11.62B | +59.32% | 0.00% |
CALM | -13.48% | $4.57B | +52.49% | 4.65% |
PRT | -13.00% | $49.92M | -3.00% | 11.26% |
LH | -12.99% | $19.78B | +11.37% | 1.24% |
K | -12.95% | $28.46B | +45.70% | 2.75% |
ED | -12.79% | $38.69B | +21.90% | 2.95% |
CPB | -12.53% | $11.75B | -8.27% | 3.73% |
GFL | -12.27% | $19.03B | +43.82% | 0.12% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BAND | 39.13% | $389.00M | -22.87% | 0.00% |
COHU | 34.44% | $719.80M | -53.00% | 0.00% |
CRBU | 31.75% | $80.08M | -81.60% | 0.00% |
NVEC | 31.19% | $307.79M | -25.80% | 6.80% |
IR | 31.13% | $32.93B | -12.52% | 0.11% |
CGNX | 30.52% | $5.18B | -25.04% | 1.15% |
MYRG | 29.92% | $1.93B | -31.60% | 0.00% |
AME | 29.66% | $39.85B | -4.63% | 0.71% |
CYRX | 29.59% | $307.45M | -66.41% | 0.00% |
SEG | 29.27% | $269.93M | -17.45% | 0.00% |
WCC | 29.09% | $7.92B | -6.78% | 1.19% |
VNT | 29.06% | $5.00B | -23.28% | 0.33% |
CACC | 28.53% | $6.37B | -2.29% | 0.00% |
YMAB | 28.49% | $217.05M | -66.71% | 0.00% |
PAX | 28.45% | $1.78B | -21.06% | 5.66% |
LAB | 28.36% | $447.20M | -55.64% | 0.00% |
MRNA | 28.31% | $10.69B | -72.61% | 0.00% |
ECVT | 28.03% | $758.19M | -41.49% | 0.00% |
FBRT | 27.87% | $1.04B | -1.86% | 11.34% |
RICK | 27.48% | $393.33M | -21.03% | 0.65% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SLGN | -0.01% | $5.51B | +7.61% | 1.57% |
OPFI | -0.01% | $845.04M | +309.60% | 0.00% |
GAN | -0.01% | $81.06M | +31.11% | 0.00% |
EC | 0.02% | $21.85B | -17.53% | 16.38% |
EZPW | -0.02% | $841.66M | +40.29% | 0.00% |
OLO | -0.02% | $1.03B | +19.27% | 0.00% |
PDD | 0.02% | $165.36B | -0.38% | 0.00% |
POST | -0.04% | $6.54B | +11.31% | 0.00% |
HQY | 0.05% | $7.68B | +11.06% | 0.00% |
EIX | -0.06% | $23.07B | -14.28% | 4.05% |
SUPN | 0.07% | $1.83B | -3.04% | 0.00% |
KSS | -0.09% | $957.33M | -68.04% | 25.37% |
APTV | -0.10% | $13.95B | -21.65% | 0.00% |
AQB | -0.12% | $2.67M | -65.15% | 0.00% |
EDSA | 0.12% | $17.13M | -43.81% | 0.00% |
YUM | 0.13% | $44.16B | +13.83% | 1.69% |
GRVY | 0.15% | $426.11M | -15.98% | 0.00% |
BERY | -0.17% | $8.17B | +29.66% | 1.68% |
VIK | -0.17% | $18.58B | +74.88% | 0.00% |
CLX | 0.18% | $18.19B | +0.54% | 3.24% |
Yahoo
ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Finnhub
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is...
Yahoo
We recently published an article titled Micro-, Small-Cap Firms Dominate Market Rally. In this article, we are going to take a look at where ALX Oncology Holdings Inc. (NASDAQ:ALXO) stands against the other stocks. The stock market pulled back to the red territory on Thursday, with all major indices posting significant losses as tariff threats continued […]
Yahoo
– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI – Presented Phase 1b/2 data demonstrating evorpacept in combination with zanidatamab generates promising anti-tumor activity in advanced breast cancer at SABCS 2024 – Announced focused development plan during R&D Day, including introduction of clinical trials evaluating e
Yahoo
ALX Oncology (ALXO) said Wednesday that it has made certain strategic changes, including reducing it
Yahoo
Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancersAdvancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025Company implements strategic prioritization, resource optimizations and reductions to extend cash runway into Q4 2026 Webcast featuring company leadership and external key opinion leaders to take place tod
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -19.89% | $416.76M | 1.43% |
TAIL | -15.59% | $87.65M | 0.59% |
VIXY | -14.25% | $195.31M | 0.85% |
IBTF | -12.84% | $2.22B | 0.07% |
BUXX | -11.68% | $234.79M | 0.25% |
IDU | -11.64% | $1.40B | 0.39% |
XLU | -10.42% | $18.06B | 0.09% |
KRBN | -10.42% | $175.08M | 0.85% |
VPU | -10.35% | $6.83B | 0.09% |
FUTY | -9.96% | $1.70B | 0.084% |
TOTL | -9.77% | $3.51B | 0.55% |
STPZ | -9.67% | $427.83M | 0.2% |
XBIL | -9.53% | $706.15M | 0.15% |
BSCQ | -8.77% | $4.26B | 0.1% |
SCMB | -8.23% | $619.52M | 0.03% |
TIPX | -7.97% | $1.68B | 0.15% |
UTWO | -7.89% | $377.39M | 0.15% |
UBND | -7.61% | $627.77M | 0.4% |
FXU | -7.57% | $1.46B | 0.64% |
WEAT | -7.33% | $115.75M | 0.28% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FTGC | 0.02% | $2.52B | 1.02% |
NYF | -0.03% | $866.32M | 0.25% |
KCCA | -0.03% | $108.04M | 0.87% |
IBHE | -0.04% | $590.52M | 0.35% |
BNO | 0.05% | $99.25M | 1% |
BWX | 0.06% | $990.94M | 0.35% |
PGHY | 0.06% | $156.01M | 0.35% |
LEMB | 0.09% | $307.83M | 0.3% |
XLP | -0.10% | $16.87B | 0.09% |
BLCN | 0.10% | $41.94M | 0.68% |
JAAA | -0.12% | $21.29B | 0.21% |
JPST | -0.14% | $31.42B | 0.18% |
FLOT | -0.15% | $8.94B | 0.15% |
OILK | 0.16% | $67.85M | 0.69% |
SPIP | 0.18% | $932.64M | 0.12% |
CCOR | 0.18% | $64.12M | 1.18% |
SCHJ | 0.21% | $513.72M | 0.03% |
EMHC | -0.22% | $199.62M | 0.23% |
CGCP | -0.24% | $4.73B | 0.34% |
NEAR | 0.24% | $3.22B | 0.25% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CPRJ | 42.74% | $48.38M | 0.69% |
RSPA | 38.84% | $292.67M | 0% |
EFAA | 35.50% | $100.03M | 0% |
QQA | 34.20% | $187.77M | 0% |
CPSJ | 32.35% | $32.91M | 0.69% |
IWC | 28.05% | $797.08M | 0.6% |
GNOM | 27.16% | $47.13M | 0.5% |
SNSR | 25.53% | $207.37M | 0.68% |
GSSC | 24.43% | $514.19M | 0.2% |
BSVO | 24.14% | $1.37B | 0.47% |
IWM | 24.02% | $62.65B | 0.19% |
VTWO | 23.98% | $10.92B | 0.07% |
IWN | 23.68% | $10.95B | 0.24% |
PRFZ | 23.51% | $2.34B | 0.39% |
VEGI | 23.46% | $88.07M | 0.39% |
KJUL | 23.42% | $155.05M | 0.79% |
PSC | 23.16% | $704.38M | 0.38% |
IWO | 23.14% | $10.72B | 0.24% |
SCHA | 22.98% | $15.94B | 0.04% |
EES | 22.84% | $575.29M | 0.38% |